ABBV · News · 20261031N

Guidance / Outlook

AbbVie Inc. · 2026-10-31 · Importance 57 · Surprise 60

AbbVie raised its full-year 2026 revenue and adjusted EPS guidance after reporting Q3 2026 results. The report says the stronger outlook rests on immunology and neuroscience products, including SKYRIZI, RINVOQ, and newer launches. It provides no revised guidance figures or specific margin or capital-expenditure outlook.

Key facts